Cancer clinical trials in the region Nouvelle-Aquitaine

371 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT05872204

Abémaciclib et létrozole chez les patientes atteintes d'un cancer de l'ovaire rare à récepteurs d'œstrogènes positifs

Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC) Other ovarian cancer Serous low grade carcinoma (LGSOC) Endometrioid carcinoma Stromal cells and sex cords tumor HR Positive Locally Advanced Metastatic 1 2 3 or more Chemotherapy Hormone therapy

Systemic Treatment-Naive

Institut Bergonié (Bordeaux)

Universitaire Ziekenhuizen KU Leuven

Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT06833073 #2024-517335-46-00

[INTerpath-011] Étude clinique de l'INTISMERAN AUTOGENE (V940) et du BCG chez les personnes atteintes d'un cancer de la vessie

Non-invasive bladder cancer Localized None 1 Surgery

Hôpital Pellegrin (Bordeaux)

Merck Sharp & Dohme LLC

Phase 2 Lung cancer #NCT06712316 #2024-515764-31-00

Sécurité, efficacité et pharmacocinétique du BNT327 en association avec la chimiothérapie et d'autres agents expérimentaux pour le cancer du poumon

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic None Systemic Treatment-Naive

ALK EGFR Immunotherapy Chemotherapy Targeted therapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Immunotherapy Chemotherapy Targeted therapy Bispecific T-cell engager antibodies

Institut Bergonié (Bordeaux)

BioNTech SE

Phase 2 Breast cancer #NCT04965766 #2023-505923-30-00

[ICARUS-BREAST] Étude du PATRITUMAB DERUXTECAN (U3-1402) dans le cancer du sein localement avancé ou métastatique inopérable

HER2 Negative HR Positive Locally Advanced Metastatic Chemotherapy Targeted therapy Hormone therapy

Centre Hospitalier Universitaire Dupuytren (Limoges)

Gustave Roussy, Campus du cancer, Grand Paris

Phase 2 Rectal cancer #NCT04749108 #2021-000414-41

[GRECCAR14] Étude évaluant la prise en charge personnalisée du cancer du rectum localement avancé

Adenocarcinoma Locally Advanced None Systemic Treatment-Naive

Institut Bergonié (Bordeaux), CHU - Haut-Lévêque - Bordeaux (Pessac), Centre Hospitalier François Mitterrand de Pau (Pau)

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Colon cancer Rectal cancer #NCT06948448 #2024-519590-19-00

Étude évaluant l’innocuité et l’efficacité de deux doses d’ONO-4578 avec Opdivo®, en association avec le protocole mFOLFOX6 et le bévacizumab, comparativement au traitement standard chez des participants atteints d’un cancer colorectal avancé non MSI-H/dMMR et PD-L1 positif.

Adenocarcinoma Locally Advanced Metastatic MSS/pMMR None Systemic Treatment-Naive

Immunotherapy

CHU - Haut-Lévêque - Bordeaux (Pessac), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers)

Ono Pharmaceutical Co. Ltd.

Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT03547973 #2023-508302-24-00

[TROPHY U-01] Étude du SACITUZUMAB GOVITECAN chez des participants atteints d'un cancer urothélial non résorbable ou propagé - Cohorte 7

Invasive bladder cancer Urothelial carcinoma Locally Advanced Metastatic None Systemic Treatment-Naive

Groupe Hospitalier Saint André (Bordeaux)

Gilead Sciences

Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT03915678 #2023-509492-16-00

[AGADIR] ATEZOLIZUMAB associé au BDB001 et à la radiothérapie chez les patients atteints de tumeurs solides avancées - Population 5

Metastatic 1 2 3 or more Immunotherapy

Systemic Treatment-Naive

Institut Bergonié (Bordeaux), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers)

Institut Bergonié

Phase 2 Lung cancer #NCT03915678 #2023-509492-16-00

[AGADIR] ATEZOLIZUMAB associé au BDB001 et à la radiothérapie chez les patients atteints de tumeurs solides avancées - Population 3

NSCLC (Non-Small Cell Lung Cancer) Metastatic 1 2 3 or more Immunotherapy

Systemic Treatment-Naive

Institut Bergonié (Bordeaux), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers)

Institut Bergonié

Phase 2 Lymphoma #NCT06534437 #2024-513098-31-00

[JASPIS-01] MEN1703 (SEL24) pour le traitement du lymphome non hodgkinien agressif à cellules B récidivant ou réfractaire

B cell lymphoma Large B cell lymphoma Indolent transformed lymphoma None 2 3 or more Chemotherapy Bispecific T-cell engager antibodies Monoclonal antibodies

Systemic Treatment-Naive

Centre Hospitalier Universitaire Dupuytren (Limoges), CHU - Haut-Lévêque - Bordeaux (Pessac)

Ryvu Therapeutics SA